ANVS - An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

• Biogen's struggles with Aduhelm - its newly approved Azheimer's therapy - have been well documented - but the company is taking some small steps in the right direction.
• Meanwhile, Cassava Sciences recently took a significant step to restoring its own reputation - and share price - after accusations of doctoring trial results.
• Several other developers - from Eli Lilly, to Anavex Life Sciences - are expecting major Alzheimer's catalysts to arrive this year and next.
• The cost of failure in Alzheimer's is high and companies riding the hype cycle are always in danger of share price collapse - witness Cortexyme and Annovis.
• Nevertheless, investors should still be interested in the Alzheimer's sector because there is genuine progress being made - although it may be best to turn a blind eye to the short term fluctuations.

For further details see: